Spots Global Cancer Trial Database for minimal residual disease persistence
Every month we try and update this database with for minimal residual disease persistence cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | NCT04062266 | Acute Myeloid L... FLT3 Gene Mutat... Hematologic and... Acute Myeloid L... Minimal Residua... Therapy-Related... | Azacitidine Venetoclax | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
